Business Context and Reporting Period
This Form 8-K Current Report is filed by Galecto, Inc. (not Damora Therapeutics, Inc.) on August 29, 2024. The report details the implementation of a reverse stock split approved by stockholders at a Special Meeting on June 20, 2024. The company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "GLTO."
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is a corporate action report regarding capital structure adjustments.
Material Changes
- Reverse Stock Split: Effective at 5:00 p.m. Eastern Time on August 29, 2024, the company executed a 1-for-25 reverse stock split.
- Share Conversion: Every 25 shares of issued and outstanding common stock were automatically converted into one share of common stock.
- Par Value: The par value per share remains unchanged at $0.00001.
- Fractional Shares: Stockholders entitled to fractional shares received rounding up to the nearest whole number.
- Equity Adjustments: Proportionate adjustments were made to the exercise price and share counts for all outstanding stock options and stock incentive plans.
- Trading Details: The stock continues to trade under the symbol "GLTO" with a new CUSIP number of 36322Q 206.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the summary is qualified by the full text of the Certificate of Amendment. The primary purpose of the filing is to notify the market of the completed capital structure change.
Investor Verification Checklist
- Verify the new CUSIP number (36322Q 206) for trading and settlement purposes.
- Confirm the adjusted number of shares held in brokerage accounts post-split.
- Review the adjusted exercise prices and share quantities for any outstanding stock options or warrants.
- Check the full text of the Certificate of Amendment (Exhibit 3.1) for any additional legal stipulations.